wtf11 Antibody

What is Integrin alpha 11 and why is it important in research?

Integrin alpha 11 (ITGA11) is a 155-160 kDa member of the integrin alpha chain family of molecules that preferentially forms a cell surface heterodimer with beta 1 integrin. It belongs to the collagen-binding group, showing particular affinity for binding to collagen I and II. ITGA11 is expressed by embryonic mesenchymal cells in development areas that incorporate or utilize collagen. In adult tissues, fibroblasts express ITGA11, and the interaction between collagen and ITGA11 likely contributes significantly to wound contraction and closure processes . The study of ITGA11 is important for understanding cell-matrix interactions, tissue development, and repair mechanisms, making antibodies against this protein valuable tools in multiple research contexts.

What applications are validated for ITGA11 antibodies?

ITGA11 antibodies have been validated for several experimental applications. Direct ELISA and Western blot analyses are the primary validated applications, with specific antibodies like the Human Integrin alpha 11 Antibody (AF4235) demonstrating effectiveness in these contexts . Western blot analysis has confirmed the detection of ITGA11 in human lung carcinoma cell lines (A549), identifying a specific band at approximately 155 kDa under reducing conditions . Additionally, research publications have utilized ITGA11 antibodies in cell lysate analysis for investigating collagen-rich environments as premetastatic niches and in studying epithelial-to-mesenchymal transition mechanisms .

How should I optimize ITGA11 antibody dilutions for Western blots?

Optimal dilution of ITGA11 antibodies for Western blot applications requires systematic testing based on your specific experimental conditions. Start with the manufacturer's recommended concentration (for example, 1 μg/mL has been successfully used with the AF4235 antibody) . For Western blot optimization:

• Test a dilution series (e.g., 0.5, 1, and 2 μg/mL) against your sample of interest

• Use appropriate positive controls (A549 human lung carcinoma cell line is a validated positive control)

• Ensure you're using the correct reducing conditions and immunoblot buffer system (Buffer Group 8 has been validated for some ITGA11 antibodies)

• Follow with an appropriate HRP-conjugated secondary antibody (such as Anti-Goat IgG for goat-derived primary antibodies)

The optimal dilution should provide a clear, specific band at approximately 155 kDa with minimal background .

What is the structure and function of ITGA11 protein?

Mature human ITGA11 is a 1167 amino acid (aa) type I transmembrane glycoprotein comprising a large 1120 aa extracellular domain (ECD) (aa 23-1142) and a short 24 aa cytoplasmic region. The ECD contains 7 FG-Gap repeats of approximately 60 amino acids each that generate beta-propellers (aa 24-650) with an intervening I domain (aa 154-345) that directly binds collagen .

Functionally, ITGA11 serves as a receptor for collagen, particularly types I and II, and mediates cell-matrix adhesion. It plays significant roles in:

• Embryonic development, particularly in areas utilizing collagen

• Fibroblast function in adult tissues

• Wound contraction and healing processes

• Potential involvement in cancer cell interactions with the extracellular matrix

Understanding this structure-function relationship is crucial when selecting antibodies targeting specific domains of the protein.

How can I validate ITGA11 antibody specificity for my research?

Validating antibody specificity is critical for ensuring reliable experimental results. For ITGA11 antibodies, consider the following comprehensive validation approach:

• Cross-reactivity testing: Assess potential cross-reactivity with related proteins. For instance, some ITGA11 antibodies show approximately 20% cross-reactivity with recombinant mouse Integrin alpha proteins in direct ELISAs .

• Knockout/knockdown controls: Use ITGA11 knockout or knockdown cell lines alongside wild-type cells to confirm signal specificity.

• Peptide competition assays: Pre-incubate the antibody with purified ITGA11 peptide before application to your samples. A true positive signal should be significantly reduced.

• Multiple antibody validation: Use antibodies targeting different epitopes of ITGA11 to confirm your findings.

• Multiple detection methods: Validate your findings using complementary approaches (e.g., immunofluorescence, Western blot, and ELISA).

This multi-faceted approach helps eliminate false positives and ensures that your observed signals truly represent ITGA11 protein.

What are the considerations for using ITGA11 antibodies in cancer research?

When utilizing ITGA11 antibodies in cancer research, several specialized considerations should be addressed:

• Expression heterogeneity: ITGA11 expression varies across cancer types and even within tumors. For instance, A549 lung carcinoma cells show detectable ITGA11 expression , but expression levels may differ in other cancer cell lines. Always validate expression in your specific cancer model.

• Microenvironment interactions: ITGA11's role in collagen binding makes it particularly relevant in studying tumor-stroma interactions. Research has identified collagen-rich environments as premetastatic niches for integrin-mediated peritoneal metastasis .

• EMT processes: ITGA11 has been implicated in epithelial-to-mesenchymal transition mechanisms, particularly in contexts involving TGF-β activation through tenascin-X . Consider how these pathways might interact in your cancer model.

• Technical challenges: Cancer tissues often have high autofluorescence and nonspecific binding. Include appropriate controls and consider antigen retrieval optimization for immunohistochemistry applications.

• Functional studies: Beyond localization, consider investigating ITGA11's functional role using blocking antibodies or comparing expression patterns with clinical outcomes.

Understanding these considerations will enhance the reliability and relevance of ITGA11 antibody applications in cancer research contexts.

How can computational modeling inform antibody specificity design?

Recent advances in computational biology offer powerful tools for designing antibodies with custom specificity profiles. Biophysics-informed models trained on experimentally selected antibodies can associate distinct binding modes with potential ligands, enabling prediction and generation of specific variants beyond those observed in experiments .

This approach involves:

• Identifying multiple binding modes: Each mode is mathematically described by parameters that depend on the experiment and sequence-specific energy functions.

• Probability modeling: The probability of antibody selection is expressed in terms of selected and unselected modes, where each mode represents a potential interaction with a specific ligand .

• Optimization for specificity: Computational algorithms can minimize energy functions associated with desired ligand binding while maximizing those associated with undesired ligands, resulting in highly specific antibody designs .

• Experimental validation: Generated sequences can be synthesized and tested experimentally to confirm the predicted specificity profiles.

This computational approach has shown success in designing antibodies with both specific high affinity for particular target ligands and cross-specificity for multiple target ligands, even when these ligands are chemically very similar .

What controls should I include when using ITGA11 antibodies?

Rigorous control implementation is essential for reliable ITGA11 antibody experiments. Include the following controls:

• Positive tissue/cell controls: A549 human lung carcinoma cell line has been validated for ITGA11 expression and can serve as a positive control . For tissue sections, fibroblast-rich areas typically express ITGA11.

• Negative controls:

  • Primary antibody omission: Apply only secondary antibody to identify non-specific secondary binding

  • Isotype controls: Use non-specific antibodies of the same isotype to identify Fc receptor binding

  • ITGA11-negative tissues or cell lines (when established)

• Specificity controls:

  • Peptide competition/blocking experiments

  • ITGA11 knockdown/knockout samples when available

• Technical controls:

  • Loading controls for Western blots (e.g., β-actin, GAPDH)

  • Multiple antibody concentrations to establish optimal signal-to-noise ratio

  • Replicate samples to assess technical variability

Proper implementation of these controls helps distinguish true ITGA11 signal from artifacts and enables confident interpretation of experimental results.

How can I quantify ITGA11 expression changes in experimental models?

Accurate quantification of ITGA11 expression changes requires careful methodological consideration:

• Western blot densitometry:

  • Use appropriate loading controls (β-actin, GAPDH)

  • Implement standard curves using recombinant ITGA11 protein at known concentrations

  • Utilize digital image analysis software with linear dynamic range

  • Normalize to total protein loading (using stain-free gels or Ponceau staining)

• qPCR for mRNA quantification:

  • Design primers spanning exon-exon junctions specific to ITGA11

  • Validate primer efficiency using standard curves

  • Use multiple reference genes for normalization

  • Apply appropriate statistical methods for fold-change calculations

• Flow cytometry for cell surface expression:

  • Optimize antibody concentration using titration experiments

  • Use median fluorescence intensity for quantification

  • Include fluorescence-minus-one (FMO) controls

  • Consider dual staining with β1 integrin to assess heterodimer formation

• Immunohistochemistry quantification:

  • Use automated image analysis for objective quantification

  • Implement H-score or Allred scoring systems for semi-quantitative analysis

  • Include calibration slides with known ITGA11 expression levels

Each method provides complementary information, and combining multiple approaches strengthens the reliability of your findings.

How does ITGA11 antibody compare with other collagen-binding integrin antibodies?

ITGA11 belongs to a family of collagen-binding integrins that includes α1β1, α2β1, α10β1, and α11β1. When selecting antibodies for research involving collagen receptors, understanding the comparative advantages is crucial:

• Specificity considerations:

  • ITGA11 antibodies typically show some cross-reactivity with mouse ITGA11 (approximately 20%)

  • This cross-reactivity may be advantageous for comparative studies across species

  • Other integrin antibodies may have different cross-reactivity profiles

• Functional distinctions:

  • ITGA11β1 preferentially binds collagen I and II

  • α1β1 has higher affinity for collagen IV

  • α2β1 binds multiple collagens with varying affinities

  • These functional differences affect interpretation of blocking experiments

• Expression pattern differences:

  • ITGA11 is predominantly expressed in embryonic mesenchymal cells and adult fibroblasts

  • α1β1 is widely expressed in many cell types

  • α2β1 is prominent on epithelial cells and platelets

  • Understanding these patterns helps in selecting appropriate experimental models

• Technical performance:

  • Antibody format (polyclonal vs. monoclonal) affects sensitivity and specificity

  • Application suitability varies across antibodies (some perform better in flow cytometry than IHC, etc.)

When designing experiments to study collagen-integrin interactions, consider using multiple antibodies targeting different integrin α subunits to comprehensively assess the contribution of each receptor type.

What is the role of ITGA11 in fibrosis and wound healing research?

ITGA11's function as a collagen receptor on fibroblasts makes it particularly relevant in fibrosis and wound healing research:

• Wound contraction mechanism: ITGA11-collagen interactions contribute significantly to wound contraction and closure . ITGA11 antibodies can help visualize and quantify this process in experimental wound models.

• Fibroblast activation: During fibrosis, fibroblasts transition to a myofibroblast phenotype, often accompanied by changes in integrin expression patterns. ITGA11 antibodies can track these phenotypic shifts in various fibrotic conditions.

• ECM remodeling: ITGA11 mediates not only adhesion to collagen but also participates in collagen remodeling. Combining ITGA11 staining with collagen hybridizing peptides can reveal areas of active matrix remodeling.

• Therapeutic targeting: Anti-ITGA11 antibodies are being explored as potential therapeutic agents to modulate excessive fibrosis. Understanding the epitope specificity and blocking capacity of different antibodies is crucial for this application.

• Cross-talk with TGF-β signaling: Research has identified connections between ITGA11 and TGF-β activation pathways, particularly through proteins like tenascin-X . This connection provides an important mechanistic link between matrix sensing and fibrotic responses.

ITGA11 antibodies thus serve as valuable tools for mechanistic studies of fibrosis progression and potential therapeutic development.

How can long-term antibody stability be assessed for ITGA11 antibodies?

Ensuring antibody stability is critical for longitudinal studies and reliable experimental outcomes. For ITGA11 antibodies, consider the following comprehensive stability assessment approach:

• Accelerated aging studies:

  • Store antibody aliquots at elevated temperatures (37°C, 45°C) for defined periods

  • Periodically test activity using standardized Western blot or ELISA protocols

  • Calculate degradation rates and extrapolate shelf-life at recommended storage conditions

• Freeze-thaw stability:

  • Subject antibody aliquots to defined numbers of freeze-thaw cycles (1, 3, 5, 10)

  • Test activity after each cycle using the same standardized assay

  • Determine the maximum acceptable number of freeze-thaw cycles

• Buffer optimization:

  • Test stability in different buffer formulations (varying pH, ionic strength, additives)

  • Identify optimal buffer conditions that maximize stability

  • Consider stabilizing additives such as glycerol, BSA, or proprietary stabilizers

• Analytical methods for structural integrity:

  • Size exclusion chromatography to detect aggregation

  • Mass spectrometry to identify chemical modifications

  • Circular dichroism to assess secondary structure maintenance

• Functional validation:

  • Epitope binding capacity using surface plasmon resonance or bio-layer interferometry

  • Target specificity assessment in complex samples

  • Correlation between analytical parameters and functional activity

Learning from studies of antibody dynamics in other systems, such as COVID-19 research where antibody stability was tracked for over 400 days, can provide valuable methodological insights for ITGA11 antibody stability assessment .

What are the considerations for using ITGA11 antibodies in multiplex immunoassays?

Incorporating ITGA11 antibodies into multiplex immunoassays requires careful optimization to ensure compatibility with other detection systems:

• Antibody labeling considerations:

  • Select fluorophores or tags with minimal spectral overlap when used with other antibodies

  • Validate that labeling does not affect the antibody's binding characteristics

  • Optimize label-to-antibody ratio for maximum sensitivity without increasing non-specific binding

• Cross-reactivity assessment:

  • Test for potential cross-reactivity with other antibodies in the multiplex panel

  • Perform single-stain controls alongside multiplex assays

  • Use antibody blocking experiments to identify and mitigate cross-reactivity issues

• Signal normalization strategies:

  • Include internal standards for each detection channel

  • Develop compensation matrices for spectral overlap correction

  • Implement appropriate statistical methods for quantifying relative expression

• Sample preparation optimization:

  • Identify fixation and permeabilization conditions compatible with all targets

  • Optimize antigen retrieval methods if necessary

  • Consider sequential staining approaches for problematic antibody combinations

• Validation approaches:

  • Compare multiplex results with single-plex assays for each target

  • Assess correlation between different detection methods

  • Include biological controls with known expression patterns

Experience from dynamic antibody analysis in COVID-19 patients demonstrates the value of multiplex approaches for tracking multiple antibody responses simultaneously, potentially offering methodological insights applicable to ITGA11 research .

What emerging technologies might enhance ITGA11 antibody applications?

The field of antibody research is rapidly evolving, with several emerging technologies poised to enhance ITGA11 antibody applications:

• Biophysics-informed computational modeling: As demonstrated in recent research, computational approaches can predict and design antibodies with customized specificity profiles, potentially enabling the creation of highly specific ITGA11 antibodies or those that can distinguish between closely related integrin family members .

• Single-cell antibody analysis: Combining ITGA11 antibodies with single-cell technologies could reveal heterogeneity in ITGA11 expression and function across cell populations, providing insights into its role in diverse cellular contexts.

• Proximity labeling approaches: Coupling ITGA11 antibodies with proximity labeling enzymes like APEX2 or BioID could identify novel interaction partners in specific cellular contexts, expanding our understanding of ITGA11's functional network.

• Quantum dot-labeled lateral flow immunoassays: Adaptation of highly sensitive detection methods, similar to those used in COVID-19 antibody research, could enable rapid, quantitative assessment of ITGA11 expression in research and potentially diagnostic applications .

• Antibody engineering for enhanced functions: Development of bispecific antibodies targeting ITGA11 and other relevant molecules could provide new tools for investigating functional interactions or developing therapeutic approaches.

These emerging technologies represent promising avenues for advancing ITGA11 research and expanding the utility of ITGA11 antibodies in both basic science and translational applications.

How might ITGA11 antibodies be used in translational research?

ITGA11 antibodies have significant potential in translational research across multiple disease contexts:

• Cancer diagnostics and prognostics: The involvement of ITGA11 in collagen-rich premetastatic niches suggests its potential as a biomarker for metastatic potential . Antibody-based detection in patient samples could help stratify cancer patients and inform treatment decisions.

• Fibrosis assessment: In conditions like pulmonary fibrosis, liver cirrhosis, or cardiac fibrosis, quantitative assessment of ITGA11-expressing activated fibroblasts could serve as a disease activity biomarker, potentially guiding therapeutic interventions.

• Wound healing applications: ITGA11's role in wound contraction and closure makes it relevant for developing diagnostic tools to assess wound healing potential or monitoring response to wound treatment strategies .

• Therapeutic antibody development: Function-blocking ITGA11 antibodies could potentially modulate fibrosis progression or cancer cell-matrix interactions, representing a novel therapeutic approach for conditions with aberrant ITGA11 activity.

• Tissue engineering: ITGA11 antibodies could help characterize engineered tissues and assess their similarity to native tissues in terms of cell-matrix interactions, potentially improving the development of tissue replacements for regenerative medicine applications.

The translation of these applications to clinical settings will require rigorous validation and standardization of ITGA11 antibody-based methods, including careful consideration of specificity, sensitivity, and reproducibility.